Cargando…

Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update

Numerous disorders of the central nervous system (CNS) are attributed to the selective death of distinct neuronal cell populations. Interestingly, in many of these conditions, a specific subset of neurons is extremely prone to degeneration while other, very similar neurons are less affected or even...

Descripción completa

Detalles Bibliográficos
Autores principales: Brichta, Lars, Greengard, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266033/
https://www.ncbi.nlm.nih.gov/pubmed/25565977
http://dx.doi.org/10.3389/fnana.2014.00152
_version_ 1782348968392392704
author Brichta, Lars
Greengard, Paul
author_facet Brichta, Lars
Greengard, Paul
author_sort Brichta, Lars
collection PubMed
description Numerous disorders of the central nervous system (CNS) are attributed to the selective death of distinct neuronal cell populations. Interestingly, in many of these conditions, a specific subset of neurons is extremely prone to degeneration while other, very similar neurons are less affected or even spared for many years. In Parkinson’s disease (PD), the motor manifestations are primarily linked to the selective, progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In contrast, the very similar DA neurons in the ventral tegmental area (VTA) demonstrate a much lower degree of degeneration. Elucidating the molecular mechanisms underlying the phenomenon of differential DA vulnerability in PD has proven extremely challenging. Moreover, an increasing number of studies demonstrate that considerable molecular and electrophysiologic heterogeneity exists among the DA neurons within the SNpc as well as those within the VTA, adding yet another layer of complexity to the selective DA vulnerability observed in PD. The discovery of key pathways that regulate this differential susceptibility of DA neurons to degeneration holds great potential for the discovery of novel drug targets and the development of promising neuroprotective treatment strategies. This review provides an update on the molecular basis of the differential vulnerability of midbrain DA neurons in PD and highlights the most recent developments in this field.
format Online
Article
Text
id pubmed-4266033
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-42660332015-01-06 Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update Brichta, Lars Greengard, Paul Front Neuroanat Neuroscience Numerous disorders of the central nervous system (CNS) are attributed to the selective death of distinct neuronal cell populations. Interestingly, in many of these conditions, a specific subset of neurons is extremely prone to degeneration while other, very similar neurons are less affected or even spared for many years. In Parkinson’s disease (PD), the motor manifestations are primarily linked to the selective, progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). In contrast, the very similar DA neurons in the ventral tegmental area (VTA) demonstrate a much lower degree of degeneration. Elucidating the molecular mechanisms underlying the phenomenon of differential DA vulnerability in PD has proven extremely challenging. Moreover, an increasing number of studies demonstrate that considerable molecular and electrophysiologic heterogeneity exists among the DA neurons within the SNpc as well as those within the VTA, adding yet another layer of complexity to the selective DA vulnerability observed in PD. The discovery of key pathways that regulate this differential susceptibility of DA neurons to degeneration holds great potential for the discovery of novel drug targets and the development of promising neuroprotective treatment strategies. This review provides an update on the molecular basis of the differential vulnerability of midbrain DA neurons in PD and highlights the most recent developments in this field. Frontiers Media S.A. 2014-12-15 /pmc/articles/PMC4266033/ /pubmed/25565977 http://dx.doi.org/10.3389/fnana.2014.00152 Text en Copyright © 2014 Brichta and Greengard. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Brichta, Lars
Greengard, Paul
Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title_full Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title_fullStr Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title_full_unstemmed Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title_short Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update
title_sort molecular determinants of selective dopaminergic vulnerability in parkinson’s disease: an update
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266033/
https://www.ncbi.nlm.nih.gov/pubmed/25565977
http://dx.doi.org/10.3389/fnana.2014.00152
work_keys_str_mv AT brichtalars moleculardeterminantsofselectivedopaminergicvulnerabilityinparkinsonsdiseaseanupdate
AT greengardpaul moleculardeterminantsofselectivedopaminergicvulnerabilityinparkinsonsdiseaseanupdate